Clinical trial
Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A…
NCT00466271 · National Taiwan University Hospital, Other · Completed
Key facts
| NCT number | NCT00466271 |
|---|---|
| Title | Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study |
| Official title | Prediction of Significant Hepatic Fibrosis in HCV Carriers With Persistently Normal Alanine Aminotransferase Levels by Splenic Arterial Pulsatility Index- A Validation Study |
| Lead sponsor | National Taiwan University Hospital, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Chronic Hepatitis C, Hepatic Fibrosis |
| Enrollment | 102 |
| Start date | Apr 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Apr 27, 2007 |
| Last update posted | Dec 23, 2008 |
| Countries | Taiwan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: